Which medication can be started in a patient with elevated transaminases and a high hemoglobin A1c?

GLP-1 Receptor Agonists or SGLT2 Inhibitors Are the Preferred First-Line Medications

For a patient with elevated liver enzymes and high A1c, start a GLP-1 receptor agonist (GLP-1 RA) as the preferred option, or alternatively an SGLT2 inhibitor, both of which are safe in liver disease and provide superior cardiovascular and metabolic benefits. 1

Rationale and Clinical Approach

Why GLP-1 RAs Are Preferred

The 2025 ADA Standards of Care explicitly recommend GLP-1 RAs and SGLT2 inhibitors as foundational therapy for type 2 diabetes, independent of baseline A1c level 1. These agents offer:

• Potent A1c reduction: 1-2% reduction when added to lifestyle modification 1
• Hepatic safety: No hepatotoxicity concerns, unlike some older agents
• Cardiovascular protection: Proven reduction in MACE, particularly stroke with GLP-1 RAs 2
• Weight loss: Beneficial for metabolic dysfunction-associated steatotic liver disease (MASLD), the most common cause of elevated transaminases 3
• Low hypoglycemia risk: Critical advantage over insulin or sulfonylureas 1

Addressing the Elevated Liver Enzymes

Elevated transaminases in diabetes patients most commonly indicate MASLD 3. GLP-1 RAs are particularly advantageous here because:

• Weight loss from GLP-1 RAs directly improves hepatic steatosis
• No hepatotoxic effects, unlike some oral agents
• Favorable metabolic profile addresses the root cause

Important caveat: If transaminases are >15x upper limit of normal with very poor glycemic control (A1c >11-16%), consider glycogenic hepatopathy 4, 5. This paradoxically improves with better glucose control, making GLP-1 RAs still appropriate.

Specific Agent Selection

Among GLP-1 RAs with proven cardiovascular benefit 1:

• Semaglutide (weekly injection or daily oral): Strongest A1c reduction and weight loss
• Dulaglutide (weekly injection): Proven stroke reduction
• Liraglutide (daily injection): Extensive cardiovascular outcome data

For SGLT2 inhibitors 1, 2:

• Empagliflozin or canagliflozin: If concurrent heart failure or chronic kidney disease
• Provide additional cardiovascular and renal protection

What About Metformin?

Do NOT start metformin if liver enzymes are significantly elevated. While traditionally first-line, metformin:

• Carries theoretical concerns in hepatic dysfunction
• Is less effective than GLP-1 RAs for A1c reduction (0.7-1.0% vs 1-2%) 1
• The 2025 guidelines explicitly state GLP-1 RAs/SGLT2 inhibitors can be initiated independent of metformin use 1

When to Consider Insulin

Reserve insulin for 1:

• A1c >10% with symptomatic hyperglycemia (polyuria, polydipsia, weight loss)
• Blood glucose ≥300 mg/dL
• Evidence of catabolism or ketosis

Even in severe hyperglycemia, GLP-1 RAs can be equally effective without the weight gain and hypoglycemia risk of insulin 6.

Practical Implementation

Starting a GLP-1 RA 7:

1. Begin at lowest dose (e.g., semaglutide 0.25 mg weekly)
2. Titrate every 4 weeks to therapeutic dose
3. Counsel on small meal portions to mitigate nausea
4. Monitor glucose closely first 4 weeks
5. Recheck liver enzymes and A1c at 3 months

If adding SGLT2 inhibitor 7:

1. Ensure eGFR >20 mL/min/1.73 m²
2. Educate on genital hygiene and dehydration symptoms
3. Consider reducing any concurrent diuretics
4. Monitor for euglycemic DKA (rare but serious)

Combination Therapy Considerations

If A1c is ≥1.5% above goal, consider starting dual therapy immediately 1:

• GLP-1 RA + SGLT2 inhibitor provides complementary mechanisms
• Both are safe in liver disease
• Addresses cardiovascular risk, weight, and glycemic control simultaneously

Avoid 1:

• Sulfonylureas (hypoglycemia risk, no cardiovascular benefit)
• Thiazolidinediones (weight gain, fluid retention, though pioglitazone has some hepatic benefit)
• DPP-4 inhibitors with GLP-1 RAs (redundant mechanism)

Monitoring Strategy

• Recheck A1c and liver enzymes at 3 months
• Expect transaminases to improve with better glycemic control and weight loss
• If transaminases worsen or remain very elevated, investigate alternative causes (viral hepatitis, autoimmune, hemochromatosis) 3
• Target A1c ≤6.5% for most patients, or 7-8% if high hypoglycemia risk 8, 1